Literature DB >> 7005902

Vascular relaxing activity and stability studies of 10,10-difluoro-13,14-dehydroprostacyclin.

Y Hatano, J D Kohli, L I Goldberg, J Fried, M M Mehrotra.   

Abstract

10,10-Difluoro-13,14-dehydroprostacyclin was compared with natural prostacyclin (prostaglandin I2, PGI2) for vascular relaxing activity in vitro on helical strips of small canine mesenteric arteries (outside diameter < 1 mm) and bovine coronary arteries (outside diameter 1.5-2.5 mm) partially contracted with prostaglanding F2 alpha as well as in vivo in pentobarbital-anesthetized dogs. The difluoro analog was 3- to 4-fold more active than PGI2 in causing relaxation of both types of strips and appeared at least equipotent to PGI2 in its blood pressure lowering effect in dogs. When incubated with Krebs' bicarbonate solution (pH 7.4) at 37 degrees C, the biological half-life of the difluoro analog was about 24 hr compared to the 10- to 15-min half-life of PGI2 under similar conditions. However, when administered intravenously to dogs, the hemodynamic effects of the difluoro analog were of the same duration as those of PGI2.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7005902      PMCID: PMC350387          DOI: 10.1073/pnas.77.11.6846

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  9 in total

1.  Chemical and biological studies on 13-dehydroprostaglandins.

Authors:  J Fried; M S Lee; B Gaede; J C Sih; Y Yoshikawa; J A McCracken
Journal:  Adv Prostaglandin Thromboxane Res       Date:  1976

Review 2.  Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis.

Authors:  S Moncada; J R Vane
Journal:  Br Med Bull       Date:  1978-05       Impact factor: 4.291

3.  Effect of prostaglandin I2 and analogs on platelet aggregation and smooth muscle contraction.

Authors:  B H Crane; T L Maish; Y T Maddox; E J Corey; I Székely; P W Ramwell
Journal:  J Pharmacol Exp Ther       Date:  1978-07       Impact factor: 4.030

4.  10,10-Difluoro-13-dehydroprostacyclin: a chemically and metabolically stabilized potent prostacyclin.

Authors:  J Fried; D K Mitra; M Nagarajan; M M Mehrotra
Journal:  J Med Chem       Date:  1980-03       Impact factor: 7.446

5.  Comparison of the effects of dopamine, isoproterenol, norepinephrine and bradykinin on canine renal and femoral blood flow.

Authors:  J L McNay; L I Goldberg
Journal:  J Pharmacol Exp Ther       Date:  1966-01       Impact factor: 4.030

6.  The chemical structure of prostaglandin X (prostacyclin).

Authors:  N Whittaker; S Bunting; J Salmon; S Moncada; J R Vane; R A Johnson; D R Morton; J H Kinner; R R Gorman; J C McGuire; F F Sun
Journal:  Prostaglandins       Date:  1976-12

7.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.

Authors:  S Moncada; R Gryglewski; S Bunting; J R Vane
Journal:  Nature       Date:  1976-10-21       Impact factor: 49.962

8.  6,9-thiaprostacyclin. A stable and biologically potent analogue of prostacyclin (PGI2)

Authors:  K C Nicolaou; W E Barnette; G P Gasic; R L Magolda
Journal:  J Am Chem Soc       Date:  1977-11-09       Impact factor: 15.419

9.  Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid.

Authors:  G J Dusting; S Moncada; J R Vane
Journal:  Prostaglandins       Date:  1977-01
  9 in total
  1 in total

Review 1.  Current issues in thrombosis prevention with antiplatelet drugs.

Authors:  G de Gaetano; C Cerletti; E Dejana; J Vermylen
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.